Stoke Therapeutics, Inc.

NasdaqGS:STOK Stock Report

Mkt Cap: US$379.7m

We’ve recently updated our valuation analysis.

Stoke Therapeutics Valuation

Is STOK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for STOK?

Other financial metrics that can be useful for relative valuation.

STOK key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue14.6x
Enterprise Value/EBITDA-1.3x
PEG Ration/a

Price to Sales Ratio vs Peers

How does STOK's PS Ratio compare to its peers?

The above table shows the PS ratio for STOK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average21.9x
FHTX Foghorn Therapeutics
22.7x50.2%US$355.7m
IPSC Century Therapeutics
56.9x47.8%US$273.1m
ADCT ADC Therapeutics
2.5x19.6%US$403.7m
PSTX Poseida Therapeutics
3.8x-32.0%US$631.7m
STOK Stoke Therapeutics
41.6x53.5%US$379.7m

Price-To-Sales vs Peers: STOK is expensive based on its Price-To-Sales Ratio (41.6x) compared to the peer average (21.9x).


Price to Earnings Ratio vs Industry

How does STOK's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.1%
n/an/an/a

Price-To-Sales vs Industry: STOK is expensive based on its Price-To-Sales Ratio (41.6x) compared to the US Biotechs industry average (12.8x)


Price to Sales Ratio vs Fair Ratio

What is STOK's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

STOK PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio41.6x
Fair PS Ratio14.4x

Price-To-Sales vs Fair Ratio: STOK is expensive based on its Price-To-Sales Ratio (41.6x) compared to the estimated Fair Price-To-Sales Ratio (14.4x).


Share Price vs Fair Value

What is the Fair Price of STOK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate STOK's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate STOK's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst STOK forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$9.52
US$33.70
+254.0%
54.5%US$83.00US$9.00n/a10
Jan ’24US$9.23
US$35.60
+285.7%
47.7%US$83.00US$20.00n/a10
Dec ’23US$7.33
US$39.70
+441.6%
49.5%US$83.00US$20.00n/a10
Nov ’23US$13.48
US$46.40
+244.2%
37.7%US$83.00US$24.00n/a10
Oct ’23US$12.84
US$51.10
+298.0%
36.7%US$83.00US$24.00n/a10
Sep ’23US$15.20
US$51.10
+236.2%
36.7%US$83.00US$24.00n/a10
Aug ’23US$14.42
US$53.20
+268.9%
35.7%US$83.00US$24.00n/a10
Jul ’23US$13.77
US$53.20
+286.3%
35.7%US$83.00US$24.00n/a10
Jun ’23US$12.03
US$54.60
+353.9%
31.6%US$83.00US$33.00n/a10
May ’23US$14.44
US$58.30
+303.7%
28.0%US$83.00US$32.00n/a10
Apr ’23US$21.81
US$58.30
+167.3%
28.0%US$83.00US$32.00n/a10
Mar ’23US$19.76
US$60.30
+205.2%
22.9%US$83.00US$41.00n/a10
Feb ’23US$18.80
US$60.30
+220.7%
22.9%US$83.00US$41.00n/a10
Jan ’23US$23.99
US$61.44
+156.1%
22.9%US$83.00US$41.00US$9.239
Dec ’22US$22.83
US$60.44
+164.8%
25.8%US$83.00US$34.00US$7.339
Nov ’22US$23.99
US$60.67
+152.9%
25.1%US$83.00US$35.00US$13.489
Oct ’22US$26.24
US$60.67
+131.2%
25.1%US$83.00US$35.00US$12.849
Sep ’22US$26.50
US$60.67
+128.9%
25.1%US$83.00US$35.00US$15.209
Aug ’22US$28.63
US$61.44
+114.6%
25.6%US$83.00US$35.00US$14.429
Jul ’22US$34.08
US$61.44
+80.3%
25.6%US$83.00US$35.00US$13.779
Jun ’22US$38.27
US$61.44
+60.6%
25.6%US$83.00US$35.00US$12.039
May ’22US$32.30
US$65.75
+103.6%
18.5%US$83.00US$45.00US$14.448
Apr ’22US$39.33
US$65.75
+67.2%
18.5%US$83.00US$45.00US$21.818
Mar ’22US$61.14
US$60.38
-1.3%
22.0%US$83.00US$42.00US$19.768
Feb ’22US$59.05
US$59.50
+0.8%
23.5%US$83.00US$42.00US$18.808
Jan ’22US$61.93
US$56.50
-8.8%
19.7%US$72.00US$42.00US$23.998

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies